Distribuzione geografica
Continente #
NA - Nord America 392
EU - Europa 385
AS - Asia 282
SA - Sud America 13
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.079
Nazione #
US - Stati Uniti d'America 392
IT - Italia 176
HK - Hong Kong 122
CN - Cina 84
SE - Svezia 70
CH - Svizzera 61
SG - Singapore 33
IN - India 24
IE - Irlanda 22
DE - Germania 18
FI - Finlandia 18
KR - Corea 15
BR - Brasile 13
SN - Senegal 6
UA - Ucraina 5
BE - Belgio 3
BG - Bulgaria 3
CZ - Repubblica Ceca 2
GB - Regno Unito 2
JP - Giappone 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
ES - Italia 1
FR - Francia 1
IL - Israele 1
PH - Filippine 1
Totale 1.079
Città #
Hong Kong 121
Bern 59
Trieste 50
Beijing 46
Boardman 37
Princeton 32
Ashburn 31
Dublin 22
Pune 19
Singapore 19
Seattle 17
Fairfield 15
Seoul 15
Boydton 14
Helsinki 13
Houston 12
São Paulo 11
Tappahannock 11
Chandler 10
Milan 10
Treviso 10
Wilmington 9
Woodbridge 8
Los Angeles 7
Shanghai 7
Dakar 6
Duino-Aurisina 6
Torviscosa 6
Ann Arbor 5
L’Aquila 5
Cambridge 4
Iesi 4
Jacksonville 4
Novara 4
Phoenix 4
West Jordan 4
Azzano Decimo 3
Brussels 3
Lappeenranta 3
New York 3
Rome 3
Sofia 3
Bolzano 2
Calenzano 2
Cividale del Friuli 2
Columbus 2
Deiva Marina 2
Dongguan 2
Favara 2
Forlì 2
Frosinone 2
Irschenberg 2
Jamaica Plain 2
Krefeld 2
Monfalcone 2
Morristown 2
Realeza 2
San Floriano del Collio 2
Sarno 2
Stockholm 2
Usti nad Orlici 2
Verona 2
Vicopisano 2
York 2
Bologna 1
Cesena 1
Chieti 1
Corridonia 1
Dearborn 1
Frankfurt am Main 1
Guangzhou 1
Guiglia 1
Islington 1
Jinan 1
Lausanne 1
London 1
Madrid 1
Mandaluyong City 1
Mumbai 1
Naples 1
Osaka 1
Pozzuolo del Friuli 1
Ravenna 1
San Diego 1
Serio 1
Tel Aviv 1
Toenisvorst 1
Tokyo 1
Tolmezzo 1
Trevignano 1
Trumbull 1
Udine 1
Venice 1
Vienna 1
Washington 1
Totale 750
Nome #
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 108
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 51
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 40
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT 37
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets 35
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial 34
179 C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 33
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 33
Can Systems Biology Advance Clinical Precision Oncology? 32
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 31
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 29
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 23
Ribociclib and Endocrine Therapy in Breast Cancer 23
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels 23
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ 22
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer 22
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 21
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 21
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemo-immunotherapy in patients with advanced melanoma 21
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype 21
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 20
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 20
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 20
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 19
Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? 19
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas 18
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer 18
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer 18
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience 17
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 17
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer 17
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis 17
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 17
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer 16
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 16
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer 16
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 16
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 15
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression 15
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer 14
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. A case report 14
The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings 14
Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer 14
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial 13
Precision medicine: PI3K targeting in advanced breast cancer 13
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy 13
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study 11
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 10
A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer 10
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy 10
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 9
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 9
[Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine] 8
Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course 8
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 7
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study 7
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 7
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy 6
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 5
CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience 5
Androgen receptor signaling pathways as a target for breast cancer treatment 5
Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer 4
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence 4
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer 4
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer 3
CTCs in early breast cancer: A path worth taking 2
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer? 2
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy 2
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy 2
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy 1
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer 1
Sorafenib for the treatment of breast cancer 1
Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients 1
Breast cancer vaccines: a clinical reality or fairy tale? 1
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy 1
Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience 1
Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer 1
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer 1
Update: current management issues in malignant melanoma 1
Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase 1
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 1
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors 1
Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients 1
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study 1
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review 1
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel 1
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors 1
Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans? 1
Diagnosis and management of neck metastases from an unknown primary 1
Radiotherapy, morphine, and bone pain: a difficult relationship? 1
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects 1
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents 1
Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer 1
Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results 1
Progress with palbociclib in breast cancer: latest evidence and clinical considerations 1
Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients 1
Circulating tumor cells in early breast cancer: A connection with vascular invasion 1
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer 1
Perfusion computed tomography for monitoring induction chemotherapy in patients with squamous cell carcinoma of the upper aerodigestive tract: correlation between changes in tumor perfusion and tumor volume 1
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 1
Totale 1.257
Categoria #
all - tutte 8.244
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.244

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194 0 0 0 0 0 0 0 0 0 0 0 4
2019/202030 2 1 1 6 2 4 3 4 2 2 2 1
2020/202125 4 13 0 1 2 0 1 1 1 0 1 1
2021/202251 1 0 0 0 0 1 0 2 1 14 3 29
2022/2023470 16 2 9 19 32 65 2 100 101 8 95 21
2023/2024676 89 43 32 63 63 54 92 112 20 35 65 8
Totale 1.275